Vistagen Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $464.0K | $303.0K | $258.0K | $244.0K | $-15.0K | $234.0K | $183.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $10.9M | $13.2M | $14.2M | $15.9M | $11.7M | $10.2M | $11.3M | $10.2M |
| SG&A Expense | $3.9M | $4.0M | $5.6M | $4.4M | $4.4M | $4.3M | $4.0M | $4.2M |
| Operating Income | $-13.3M | $-16.7M | $-19.5M | $-20.1M | $-15.8M | $-14.5M | $-15.1M | $-14.2M |
| Operating Margin | -904.3% | -3,604.1% | -6,450.8% | -7,772.5% | -6,477.0% | 96,633.3% | -6,461.5% | -7,774.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-13.0M | $-16.3M | $-18.9M | $-19.4M | $-15.1M | $-13.6M | $-14.1M | $-13.0M |
| Income Tax Expense | $0 | $7.0K | $0 | $0 | $0 | $0 | $0 | $7.0K |
| Net Income | $-13.0M | $-16.3M | $-18.9M | $-19.4M | $-15.1M | $-13.6M | $-14.1M | $-13.0M |
| Net Margin | -882.8% | -3,507.3% | -6,237.3% | -7,526.0% | -6,186.5% | 90,900.0% | -6,020.9% | -7,082.5% |
| EPS (Basic) | $-0.30 | $-0.37 | $-0.45 | $-0.54 | $-0.47 | $-0.44 | $-0.46 | $-0.42 |
| EPS (Diluted) | $-0.30 | $-0.37 | $-0.45 | $-0.54 | $-0.47 | $-0.44 | $-0.46 | $-0.42 |
| Shares Outstanding (Basic) | 43.0M | 38.1M | 42.2M | 35.7M | 31.9M | 30.9M | 30.7M | 30.6M |
| Shares Outstanding (Diluted) | 43.0M | 38.1M | 42.2M | 35.7M | 31.9M | 30.9M | 30.7M | 30.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |